Levemir (insulin detemir rDNA origin) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 62 Diseases   27 Trials   27 Trials   847 News 


«12345678910»
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Trial completion date, Trial primary completion date:  IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) -  Feb 13, 2023   
    P=N/A,  N=240, Active, not recruiting, 
    Detemir is useful in diabetic dogs with other comorbidities and can be considered an alternative treatment in poorly controlled diabetic dogs. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Journal:  Clinical Evidence and Practice-Based Guidelines on the Utility of Basal insulin combined Oral therapy (metformin and glimepiride) in the current era. (Pubmed Central) -  Jan 11, 2023   
    Compared with other long-acting insulin analogues (insulin glargine and insulin detemir), insulin degludec was associated with a significantly decreased FPG, with lower prevalences of overall and nocturnal hypoglycemia. These current clinical practice guidelines highlight the efficacy and safety of basal insulin combination therapy with various available basal insulins including neutral protamine hagedorn, detemir, glargine and degludec in addition to metformin and glimepiride therapy.
  • ||||||||||  100 years with insulin. Implementation of analogs and technology in our environment (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_812;    
    Of the 6 pumps, they use lispro (4/6), aspartic (1/6) and another glulisine (1/6) Of the MDIs, as slow analogs NPH 0/65, detemir 12/65 (85% are <6 years), U100 10/65, U300 35/65 liraglutide 8/65...Of the MDIs, such as fast analogues è Actrapid 0/65, lispro 30/65 (1 U200 off labell per dose), aspartic 10/65, ultrafast (15/65) and glulisine 10/65 The indication has been for age, comfort, dose / need for stockings and a pen for this purpose and switch due to poor adjustment of the previous analog...There was no impediment by medical inspection in any prescription except in 1 case (belonging to another health area) with BAQSIMI Previous severe hypoglycemia with previous loss of consciousness in <5% of cases (0.03 patient / year cases)... We assume that this study may have some shortcomings due to the size of the sample, but our study demonstrates the implementation of the most modern analogs in the office, of measurement technology, but the need to advance in the use of insulin pumps.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Journal:  Site-Specific Albumin-Selective Ligation to Human Serum Albumin under Physiological Conditions. (Pubmed Central) -  Nov 10, 2022   
    Furthermore, these RAEs are orthogonal to the maleimide-based conjugation strategy for Cys34 of HSA. Together, these attributes make the RAEs the promising leads to further develop in vitro and in vivo HSA bioconjugation strategies for numerous biomedical applications.
  • ||||||||||  insulin icodec (OI287GT) / Novo Nordisk
    Review, Journal:  Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials. (Pubmed Central) -  Oct 26, 2022   
    (ClinicalTrials. A brighter prospect of once-weekly insulin icodec is on the card in particular in type 2 diabetes in terms of reducing injection pricks by >85% vs. once-daily basal insulin analogs, although few unknowns still exist.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Enrollment closed:  CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) -  Oct 19, 2022   
    P3,  N=100, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
    Journal:  Quantification of Insulin Analogs by Liquid Chromatography-High-Resolution Mass Spectrometry. (Pubmed Central) -  Sep 29, 2022   
    Here we describe a liquid chromatography-tandem high-resolution accurate mass (LC-HRAM) for the highly specific and independent quantification of insulin and its synthetic analogs including aspart, detemir, glargine, glulisine, and lispro. This method utilizes antibody affinity extraction followed by analysis on a high-resolution accurate mass spectrometer.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Medical Optimization Model of Management of Type 1 Diabetes in Mexico (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1996;    
    Available treatment strategies in Mexico targeting hypertension, hyperglycemia, and hyperlipidemia may improve health outcome in patients with T1DM. Using optimally available treatments based on the best outcomes may led to important savings to the Mexican health system.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
    Cost-Minimization Analysis for Treating T1DM and T2DM With Toujeo in Turkiye (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_520;    
    Cost of outpatient visits, hospitalization and other interventions, incidence complications, and medicines in the use of IGI-300U/mL offer lower costs compared to other treatments. The results of the cost-minimization analysis show that IGI-300U/mL is both cheaper and more effective than other treatments for T1DM-T2DM in Turkiye.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Trial completion:  Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (clinicaltrials.gov) -  Aug 29, 2022   
    P3,  N=30, Completed, 
    The results of the cost-minimization analysis show that IGI-300U/mL is both cheaper and more effective than other treatments for T1DM-T2DM in Turkiye. Unknown status --> Completed
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk, NN1213 / Novo Nordisk
    Trial completion:  The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) -  Aug 10, 2022   
    P2/3,  N=66, Completed, 
    The only statistically significant differences were less weight gain in type 2 diabetes and fewer episodes of severe hypoglycemia in type 1 diabetes with insulin detemir. Active, not recruiting --> Completed
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    A Case of Hypoglycemia and Diabetic Ketoacidosis in an Adult with Down Syndrome () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_968;    
    Our case illustrates the difficulty of glycemic control in patients with Down syndrome and diabetes complicated by caregiver fatigue, intellectual disability, and a complex insulin regimen. Clinicians should aim for a balance between glycemic control and treatment regimen simplicity.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Clinical, Journal:  Insulin Dosage Adjustments After Initiation of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes. (Pubmed Central) -  Jul 8, 2022   
    There was a median reduction in patients receiving glargine (50 units vs. 44 units) and detemir (29 units vs. 21.5 units)...The median HbA1C in our patient population was >8%. Consider a ≥10% reduction in the overall basal insulin dose upon initiation of GLP-1RA in patients with a HbA1C >8%.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Specifically, Levemir… (Twitter) -  Jun 17, 2022   
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Review, Journal:  One hundred years of insulin: Is it time for smart? (Pubmed Central) -  May 14, 2022   
    For a formulation to be an effective and safe "basal" insulin, its action should be roughly the same every hour of the day. Currently, only insulin glargine U300 and insulin degludec meet this standard in dogs, whereas in cats, insulin glargine U300 is the closest option.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Glycemic Control with Ultrarapid Lispro (URLi) vs. Lispro in Children and Adolescents with T1D: PRONTO-Peds (Hall E-2 (Level 1); Board No. 38) -  May 11, 2022 - Abstract #ADA2022ADA_2581;    
    URLi dosed at the start of meals or up to 20 min after the start of meals showed noninferiority for HbA1c change from baseline vs. lispro. URLi dosed at the beginning of meals showed lower PPG at 1 h after breakfast and dinner and lower 1 h postmeal glucose daily mean vs. lispro.
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Journal:  Insulin Detemir vs NPH in Pregnancy. (Pubmed Central) -  May 6, 2022   
    URLi dosed at the beginning of meals showed lower PPG at 1 h after breakfast and dinner and lower 1 h postmeal glucose daily mean vs. lispro. No abstract available
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Enrollment open, Trial initiation date:  DETERMINE: Detemir vs NPH (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=336, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Feb 2022
  • ||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
    Biomarker, Clinical, Retrospective data, Review, Journal:  Insulin Allergy to Detemir Followed by Rapid Onset of Diabetic Ketoacidosis: A Case Report and Literature Review. (Pubmed Central) -  Apr 7, 2022   
    Glycaemic control in the patient initially improved after being started on subcutaneous insulin infusion pump with reduced insulin requirements. However, after a year on pump therapy, localised insulin hypersensitivity reactions started, and glycaemic control gradually deteriorated.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Journal:  The Ongoing Evolution of Basal Insulin Therapy over 100 Years and its Promise for the Future. (Pubmed Central) -  Apr 1, 2022   
    However, it may be that we may have reached the achievable limit in the context of an "open-loop" approach, such that only with the addition of closed loop control will we be able to achieve physiologic basal insulin replacement. In this review, we will examine the evolution of basal insulin therapy over the past 100?years and its implications for patient care and outcomes in current practice and the future.